B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

KCNQ2

MOLECULAR TARGET

potassium voltage-gated channel subfamily Q member 2

UniProt: O88943NCBI Gene: 17084813 compounds

KCNQ2 (potassium voltage-gated channel subfamily Q member 2) is targeted by 13 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting KCNQ2

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Chlorhexidine1.614
2Clotrimazole1.614
3Hexachlorophene1.614
4vinpocetine1.102
5amn0821.102
6Oleic Acid0.691
717 alpha-Hydroxyprogesterone Caproate Hydroxyprogesterone derivative that acts as0.691
8Calcimycin0.691
9Fenofibrate0.691
10Loratadine0.691
11Nisoldipine0.691
12Sphingosine0.691
13Thioridazine0.691

About KCNQ2 as a Drug Target

KCNQ2 (potassium voltage-gated channel subfamily Q member 2) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 13 compounds with documented KCNQ2 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

KCNQ2 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.